Brammer Bio has unveiled plans to build-out a 50,000 sq. ft. facility dedicated to late phase development, including Phase III and commercial production of viral vector-based and cell-based advanced therapies. The Lexington, MA facility will be qualified and operational by Q2 of 2017. More than $50 million will be invested in the build-out of operations and growing the staff by up to 200, according to the company. “We’re delighted to bring to reality full scale gene and cell therapy productio...